+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Osteoporosis (Musculoskeletal) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 401 Pages
  • August 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5438145
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide 'Osteoporosis - Drugs In Development, 2021', provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights


This report provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 17, 9, 22, 3, 69, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 14 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Osteoporosis - Overview

Osteoporosis - Therapeutics Development

Osteoporosis - Therapeutics Assessment

Osteoporosis - Companies Involved in Therapeutics Development

Osteoporosis - Drug Profiles

Osteoporosis - Dormant Projects

Osteoporosis - Discontinued Products

Osteoporosis - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Osteoporosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Osteoporosis - Pipeline by Abiogen Pharma SpA, 2021
  • Osteoporosis - Pipeline by Ablynx NV, 2021
  • Osteoporosis - Pipeline by Abreos Biosciences Inc, 2021
  • Osteoporosis - Pipeline by Aclaris Therapeutics Inc, 2021
  • Osteoporosis - Pipeline by Addpharma Inc, 2021
  • Osteoporosis - Pipeline by Aerami Therapeutics Inc, 2021
  • Osteoporosis - Pipeline by Affilogic SAS, 2021
  • Osteoporosis - Pipeline by AgeX Therapeutics Inc, 2021
  • Osteoporosis - Pipeline by AlphaMab Co Ltd, 2021
  • Osteoporosis - Pipeline by Amgen Inc, 2021
  • Osteoporosis - Pipeline by Angitia Biopharmaceuticals, 2021
  • Osteoporosis - Pipeline by Aryogen Pharmed Co, 2021
  • Osteoporosis - Pipeline by Bainan Biotech ApS, 2021
  • Osteoporosis - Pipeline by Beryl Therapeutics Inc, 2021
  • Osteoporosis - Pipeline by Better Life Pharmaceuticals Inc, 2021
  • Osteoporosis - Pipeline by Bone Biologics Corp, 2021
  • Osteoporosis - Pipeline by Cadila Healthcare Ltd, 2021
  • Osteoporosis - Pipeline by Cellatoz Therapeutics Inc, 2021
  • Osteoporosis - Pipeline by Celltrion Inc, 2021
  • Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, 2021
  • Osteoporosis - Pipeline by Citragen Pharmaceuticals Inc, 2021
  • Osteoporosis - Pipeline by CK Biotech Inc, 2021
  • Osteoporosis - Pipeline by Clayton Biotechnologies Inc, 2021
  • Osteoporosis - Pipeline by Corium Inc, 2021
  • Osteoporosis - Pipeline by CSPC Pharmaceutical Group Ltd, 2021
  • Osteoporosis - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
  • Osteoporosis - Pipeline by Dong Wha Pharma Co Ltd, 2021
  • Osteoporosis - Pipeline by Dongkook Pharmaceutical Co Ltd, 2021
  • Osteoporosis - Pipeline by Eden Biologics Inc, 2021
  • Osteoporosis - Pipeline by Eli Lilly and Co, 2021
  • Osteoporosis - Pipeline by Endoceutics Inc, 2021
  • Osteoporosis - Pipeline by Enesi Pharma Ltd, 2021
  • Osteoporosis - Pipeline by Entera Bio Ltd, 2021
  • Osteoporosis - Pipeline by Enteris BioPharma Inc, 2021
  • Osteoporosis - Pipeline by Enzene Biosciences Ltd, 2021
  • Osteoporosis - Pipeline by Enzo Biochem Inc, 2021
  • Osteoporosis - Pipeline by Epygen Biotech Pvt Ltd, 2021
  • Osteoporosis - Pipeline by Evgen Pharma Plc, 2021
  • Osteoporosis - Pipeline by Fresenius Kabi SwissBioSim GmbH, 2021
  • Osteoporosis - Pipeline by Galapagos NV, 2021
  • Osteoporosis - Pipeline by Gbiologics Inc, 2021
  • Osteoporosis - Pipeline by Genor BioPharma Co Ltd, 2021
  • Osteoporosis - Pipeline by GlycoNex Inc, 2021
  • Osteoporosis - Pipeline by GPN Therapeutics Inc, 2021
  • Osteoporosis - Pipeline by Haoma Medica Ltd, 2021
  • Osteoporosis - Pipeline by Helixmith Co Ltd, 2021
  • Osteoporosis - Pipeline by Hengenix Biotech Inc, 2021
  • Osteoporosis - Pipeline by Histide AG, 2021
  • Osteoporosis - Pipeline by HNB Therapeutics LLC, 2021
  • Osteoporosis - Pipeline by Hualan Biological Engineering Inc, 2021
  • Osteoporosis - Pipeline by Huons Global Co Ltd, 2021
  • Osteoporosis - Pipeline by IMGENEX India Pvt Ltd, 2021
  • Osteoporosis - Pipeline by Immunwork Inc, 2021
  • Osteoporosis - Pipeline by InnoPharmaScreen Inc, 2021
  • Osteoporosis - Pipeline by Innovent Biologics Inc, 2021
  • Osteoporosis - Pipeline by InSight Biopharmaceuticals Ltd, 2021
  • Osteoporosis - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co Ltd, 2021
  • Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2021
  • Osteoporosis - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
  • Osteoporosis - Pipeline by Shanghai Mab Venture Biopharm Co Ltd, 2021
  • Osteoporosis - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2021
  • Osteoporosis - Pipeline by Shin Poong Pharm Co Ltd, 2021
  • Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, 2021
  • Osteoporosis - Pipeline by Surrozen Inc, 2021
  • Osteoporosis - Pipeline by Suzhou Stainwei Biotech Inc, 2021
  • Osteoporosis - Pipeline by Taithera Inc, 2021
  • Osteoporosis - Pipeline by TempestTx, Inc., 2021
  • Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, 2021
  • Osteoporosis - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
  • Osteoporosis - Pipeline by The National Institute for Biotechnology in the Negev Ltd, 2021
  • Osteoporosis - Pipeline by The United Laboratories International Holdings Ltd, 2021
  • Osteoporosis - Pipeline by Tritech Biopharmaceuticals Co Ltd, 2021
  • Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, 2021
  • Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, 2021
  • Osteoporosis - Pipeline by USV Pvt Ltd, 2021
  • Osteoporosis - Pipeline by Vibe Pharmaceuticals LLC, 2021
  • Osteoporosis - Pipeline by Vidasym Inc, 2021
  • Osteoporosis - Pipeline by Viking Therapeutics Inc, 2021
  • Osteoporosis - Pipeline by Wuxi Hebang Biotechnology Co Ltd, 2021
  • Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, 2021
  • Osteoporosis - Pipeline by Zosano Pharma Corp, 2021
  • Osteoporosis - Dormant Projects, 2021
  • Osteoporosis - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Osteoporosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abiogen Pharma SpA
  • Ablynx NV
  • Abreos Biosciences Inc
  • Aclaris Therapeutics Inc
  • Addpharma Inc
  • Aerami Therapeutics Inc
  • Affilogic SAS
  • AgeX Therapeutics Inc
  • AlphaMab Co Ltd
  • Amgen Inc
  • Angitia Biopharmaceuticals
  • Aryogen Pharmed Co
  • Bainan Biotech ApS
  • Beryl Therapeutics Inc
  • Better Life Pharmaceuticals Inc
  • NovMetaPharma Co Ltd
  • Omeros Corp
  • Oncosimis Biotech Pvt Ltd
  • Ortho Regenics Pvt Ltd
  • OssiFi Inc
  • Paras Biopharmaceuticals Finland Oy
  • PhytoHealth Corp
  • Prestige BioPharma Ltd
  • Qilu Pharmaceutical Co Ltd
  • R-Pharm
  • Regenerative Arthritis & Bone Medicine Inc
  • Reliance Life Sciences Pvt Ltd
  • Reven Pharmaceuticals Inc
  • Ribomic Inc
  • Richter Gedeon Nyrt
  • Samsung Bioepis Co Ltd
  • Sandoz International GmbH
  • Shaanxi Micot Technology Co Ltd
  • Shandong Danhong Pharmaceutical Co Ltd
  • Shanghai Biomabs Pharmaceuticals Co Ltd
  • Shanghai Celgen Bio-Pharmaceutical Co Ltd
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Mab Venture Biopharm Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Shin Poong Pharm Co Ltd
  • Stelis Biopharma Pvt Ltd
  • Surrozen Inc
  • Suzhou Stainwei Biotech Inc
  • Taithera Inc
  • TempestTx, Inc.
  • Terpenoid Therapeutics Inc
  • Teva Pharmaceutical Industries Ltd
  • The National Institute for Biotechnology in the Negev Ltd
  • The United Laboratories International Holdings Ltd
  • Tritech Biopharmaceuticals Co Ltd
  • TSH Biopharm Corporation Ltd
  • Uni-Bio Science Group Ltd
  • USV Pvt Ltd
  • Vibe Pharmaceuticals LLC
  • Vidasym Inc
  • Viking Therapeutics Inc
  • Wuxi Hebang Biotechnology Co Ltd
  • Yooyoung Pharm Co Ltd
  • Zosano Pharma Corp